While Western medicine has spent decades prescribing amphetamine-based stimulants for focus and benzodiazepines for anxiety, Russian scientists were developing something different: neuropeptides that work directly with the brain's own signaling pathways. Semax and Selank have been used clinically in Russia for over 40 years. In 2026, the Western world is finally paying attention — and the engagement data suggests this conversation is just getting started.
What Are Semax and Selank?
Semax and Selank are synthetic neuropeptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Despite being relatively unknown in the US until recently, both compounds have an extensive research history and established clinical use in Russia and Eastern Europe.
Semax is a synthetic analogue of ACTH (adrenocorticotropic hormone) — specifically a heptapeptide derived from the 4-10 fragment of ACTH that retains its cognitive effects without the hormonal activity. It was originally developed in the 1980s for stroke recovery and cognitive impairment, and is currently registered as a drug in Russia for ischemic stroke, optic nerve disease, and cognitive dysfunction.
Selank is a synthetic analogue of the endogenous immunomodulatory peptide tuftsin, with an additional stabilizing sequence. Developed alongside Semax at the same institute, Selank is registered in Russia as an anxiolytic — an anti-anxiety compound — with clinical use for generalized anxiety disorder, neurasthenia, and cognitive dysfunction secondary to anxiety.
Both are administered intranasally — as nasal drops — making them among the most accessible peptides in terms of delivery. Intranasal administration allows direct access to the brain via the olfactory pathway, bypassing the blood-brain barrier that blocks many compounds from reaching the CNS.
How Semax Works: The Neuroscience
Semax's primary mechanism involves BDNF (brain-derived neurotrophic factor) upregulation. BDNF is often called the brain's "growth hormone" — it promotes the survival of existing neurons, encourages the growth of new synaptic connections, and is essential for learning, memory consolidation, and long-term cognitive function. BDNF levels decline with age, chronic stress, poor sleep, and sedentary behavior — the same factors associated with cognitive decline and depression.
Semax increases BDNF in the hippocampus and frontal cortex — the regions most critical for memory and executive function — within hours of administration. Studies in animal models show that Semax-treated subjects demonstrate significantly improved maze performance, faster learning curves, and better retention compared to controls.
Additional mechanisms include:
- Dopaminergic and serotonergic modulation: Semax increases dopamine and serotonin turnover in key brain regions — supporting motivation, mood, and sustained attention without the sharp peaks and crashes of stimulant drugs.
- Neuroprotection: Semax reduces oxidative stress in neurons and has demonstrated protective effects against excitotoxicity — the neuronal damage caused by excessive glutamate signaling, which occurs in strokes, traumatic brain injury, and chronic stress.
- Cholinergic enhancement: Semax potentiates acetylcholine signaling — the neurotransmitter most directly associated with working memory and attention.
The subjective experience users describe is consistent with this mechanistic picture: sharper focus, faster information processing, improved recall, and a sense of mental clarity — without the jitteriness, appetite suppression, or cardiovascular effects of traditional stimulants.
How Selank Works: Calm Without Sedation
Selank operates through a distinct but complementary set of mechanisms, primarily targeting anxiety without impairing cognitive performance. This combination — anxiolytic effect with preserved or enhanced cognition — is what makes Selank so different from conventional anti-anxiety options.
GABA-A modulation: Selank modulates the GABA-A receptor — the same receptor targeted by benzodiazepines like Xanax and Valium. But where benzodiazepines cause sedation, cognitive impairment, and dependence through their specific binding pattern, Selank's interaction with GABA-A is more nuanced, producing anxiolysis without the sedative and amnestic effects. Multiple studies confirm that Selank-treated subjects show reduced anxiety scores equivalent to or exceeding benzodiazepines — with no impairment of memory or reaction time.
BDNF upregulation: Like Semax, Selank also increases BDNF — creating a mechanism by which anxiety reduction and cognitive enhancement occur simultaneously. This is the opposite of the cognitive trade-off that accompanies most anxiolytics.
IL-6 and immune modulation: Selank has immunomodulatory properties via its tuftsin-derived structure. It upregulates IL-6 in a context-dependent, regulated manner that supports immune surveillance without promoting chronic inflammation. In patients whose anxiety has an inflammatory or post-infectious component, this mechanism may be particularly relevant.
Enkephalin regulation: Selank has been shown to inhibit enkephalin-degrading enzymes, increasing the availability of endogenous enkephalins — natural opioid peptides that modulate emotional regulation and stress response. This may contribute to its anxiolytic effects without engaging the classical opioid reward pathway.
Semax vs. Adderall: A Fair Comparison
The comparison to Adderall is inevitable given that both are used for focus and cognitive performance — but the mechanisms and risk profiles are fundamentally different:
- Mechanism: Adderall causes massive, rapid release of dopamine and norepinephrine — flooding synapses with neurotransmitters far above baseline. Semax modulates BDNF and supports normal neurotransmitter cycling. One is a flood; the other is a current optimization.
- Addiction risk: Adderall carries significant dependence risk through dopamine receptor downregulation and tolerance development. Semax shows no dependence signal in either animal or human research.
- Cardiovascular effects: Adderall significantly elevates heart rate and blood pressure. Semax has no clinically significant cardiovascular effects.
- Sleep disruption: Adderall frequently disrupts sleep architecture. Semax does not interfere with sleep and some users report improved sleep quality.
- Crash: Adderall's dopamine surge is followed by a well-documented rebound period as dopamine depletes. Semax users consistently report no crash effect.
The trade-off: Adderall produces a more immediate and forceful focus effect. Semax is subtler — a sharpening rather than an amplification. For patients who need high-octane cognitive performance in the short term, Adderall's profile may still be preferable. For sustained, long-term cognitive optimization without dependency risk, Semax presents a meaningfully different option.
The Semax + Selank Stack
In practice, Semax and Selank are frequently used together — and the rationale is mechanistically sound. Semax drives cognitive performance through BDNF upregulation and neurotransmitter optimization. Selank removes the anxiety that impairs performance under pressure. The combination delivers the dual benefit that neither compound fully achieves alone: sharpened cognition in a calm, regulated neurological state.
This stack is particularly relevant for:
- Professionals in high-stakes environments (legal, medical, financial) where performance pressure is constant
- Students managing the cognitive demands of intensive academic programs
- Adults managing work-related anxiety that blunts cognitive performance
- Anyone tapering from benzodiazepines who needs an anxiolytic bridge without dependence risk
In research protocols, Semax and Selank are typically administered separately — Semax in the morning for cognitive activation and Selank as needed for anxiety management or in the evening for overnight BDNF support. Your physician can help structure the timing based on your specific goals.
Delivery: Why Intranasal Matters
Most peptides are administered subcutaneously because they are degraded in the gastrointestinal tract before reaching systemic circulation. Semax and Selank take a different path: intranasal delivery via the olfactory nerve provides direct CNS access that oral and even parenteral administration cannot replicate for these specific compounds.
The olfactory epithelium is one of the few places in the human body where the central nervous system is directly accessible from the external environment. Intranasal peptides can bypass the blood-brain barrier through axonal transport along olfactory nerves — achieving CNS concentrations that make them effective at doses far lower than would be required via any other route.
This delivery mechanism also means onset is rapid — most users report effects within 15-30 minutes of intranasal administration — and that the dosing process is straightforward (2-3 drops per nostril, typically once or twice daily).
Semax & Selank at PepGenex
PepGenex offers Semax and Selank through our physician-supervised peptide protocols, prescribed and fulfilled via FDA-registered compounding pharmacies. As with all peptide therapies, our licensed providers will assess your health history and goals before recommending any protocol. If you're exploring cognitive optimization, anxiety management, or neuroprotective strategies, Semax and Selank represent one of the most evidence-backed and overlooked options currently available.
This content is for informational purposes only and does not constitute medical advice. Consult a licensed physician before starting any peptide therapy.